+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Solid Tumors Target Proteins Market - Global Forecast 2026-2032- Product Image
Solid Tumors Target Proteins Market - Global Forecast 2026-2032- Product Image
New

Solid Tumors Target Proteins Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126474
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Solid Tumors Target Proteins Market is undergoing a pivotal transformation, driven by advancements in oncology research, diagnostic technology, and manufacturing capabilities. Senior decision-makers increasingly recognize the importance of integrating robust biological insights with resilient operations to maintain a competitive edge across diverse geographies.

Market Snapshot: Solid Tumors Target Proteins Market

The Solid Tumors Target Proteins Market expanded from USD 1.62 billion in 2025 to USD 1.78 billion in 2026. Sustained double-digit compound annual growth is expected to propel the market to USD 3.18 billion by 2032. This trajectory mirrors industry-wide adoption of precision oncology, a growing emphasis on stringent biological validation, and heightened operational complexity influencing which therapeutic programs move forward. Companies in this sector face accelerating innovation cycles, demanding that strategic decisions align with shifting regulatory standards, evolving payer expectations, and the need for reliable diagnostic integration across major markets.

Scope & Segmentation of the Solid Tumors Target Proteins Market

This report delivers actionable intelligence across key market dimensions, supporting executive-level decisions in development, investment, and operational planning. The study segments the Solid Tumors Target Proteins Market by biological target, modality, clinical indication, end user, development stage, regional footprint, and technological ecosystem. All findings are structured to align with the practical concerns of commercial stakeholders and portfolio strategists.

  • Target Class: Evaluation of cell-surface antigens, immune-regulatory proteins, pathways in growth factor or receptor signaling, DNA repair mediators, and intracellular oncogene drivers.
  • Therapeutic Modality: Analysis of small molecule drugs, monoclonal and bispecific antibodies, antibody-drug conjugates, T-cell engagers, and emerging protein degraders.
  • Indication: Insights by tumor types such as breast, lung, colorectal, prostate, ovarian, pancreatic, melanoma, as well as head and neck cancers; reveals dependencies and unique clinical barriers for each.
  • End User: Coverage includes biopharmaceutical companies, innovative biotech firms, contract research organizations, academic centers, translational labs, and diagnostic solution providers.
  • Development Stage: Spans from target discovery through advanced clinical investigation, clarifying how requirements and risk mitigation evolve throughout the product lifecycle.
  • Geography: Regional segmentation across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, reflecting differences in regulatory frameworks, access to diagnostics, and the structure of local clinical development ecosystems.
  • Technology Use: Overview of enabling trends including multi-omic profiling for enhanced target evaluation, spatial biology and single-cell analytics to address tumor heterogeneity, companion diagnostics for individualized care, and advanced manufacturing platforms to support next-generation therapies.

Strategic Insights for Decision Makers

  • Evaluations of target proteins increasingly account for their role within dynamic biological systems, placing priority on those that can be combined or adapted for durable therapeutic impact.
  • Early integration of diagnostics is now fundamental, facilitating both biomarker-driven patient selection and adaptive, real-time clinical trial management.
  • Local regulatory requirements, reimbursement practices, and manufacturing ecosystems directly influence the viability of target proteins for commercial development in each region.
  • Organizations able to align diagnostic platforms, supply chain readiness, and manufacturing capabilities are positioned to sustain competitive advantage as market requirements evolve.
  • Successful development programs are characterized by their ability to mitigate late-stage attrition, with validation, compliance, and manufacturability considered at each step to reduce exposure to costly failures.

Tariff Impact and Operational Implications

Recent tariffs introduced in the United States beginning in 2025 have increased the complexity of sourcing and manufacturing for solid tumor protein therapeutics. This shift affects the availability and cost of critical components across the oncology supply chain. Companies with mature chemistry, manufacturing, and controls (CMC) frameworks, as well as strong supplier relationships, can absorb such pressures more effectively. In response, regional manufacturing expansion and "friend-shoring" strategies are becoming prevalent, although these introduce new layers of regulatory and quality oversight for operational teams.

Methodology & Data Sources

Findings presented in this analysis are drawn from systematic reviews of peer-reviewed publications, focused examinations of clinical trial registries, and analysis of regulatory policy updates. Expert interviews with stakeholders—including discovery scientists, clinical developers, regulatory leaders, and supply chain managers—provide context and validation, ensuring results reflect actual market execution.

Why This Report Matters

  • Supports senior leaders in benchmarking their protein target pipelines and operational strategies against current market and regulatory benchmarks.
  • Enables investment teams and project leaders to identify regionally actionable targets and strengthen diagnostic or manufacturing partnerships for strategic growth.
  • Equips business development and C-suite stakeholders with insights to evaluate portfolio risk and expansion opportunities across technology and geography.

Conclusion

The Solid Tumors Target Proteins Market is evolving into a more integrated space where cohesive strategies in biology, diagnostics, and operations define sustainable performance. Organizations embracing system-level approaches are best positioned to achieve balanced growth and long-term innovation.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Solid Tumors Target Proteins Market, by Indication
8.1. Breast Cancer
8.1.1. Her2 Positive
8.1.2. Hormone Receptor Positive
8.1.3. Triple Negative
8.2. Colorectal Cancer
8.3. Lung Cancer
8.3.1. Non-Small Cell Lung Cancer
8.3.2. Small Cell Lung Cancer
8.4. Ovarian Cancer
8.5. Prostate Cancer
9. Solid Tumors Target Proteins Market, by Target Class
9.1. Checkpoint Inhibitors
9.1.1. Ctla-4
9.1.2. Pd-1
9.1.3. Pd-L1
9.2. Dna Repair Proteins
9.3. Growth Factor Receptors
9.3.1. Egfr
9.3.2. Her2
9.3.3. Vegfr
9.4. Kinase Inhibitors
9.4.1. Serine Threonine Kinase Inhibitors
9.4.2. Tyrosine Kinase Inhibitors
9.5. Nuclear Receptors
10. Solid Tumors Target Proteins Market, by Therapeutic Modality
10.1. Antibody Drug Conjugates
10.2. Car T
10.3. Monoclonal Antibodies
10.3.1. Chimeric
10.3.2. Fully Human
10.3.3. Humanized
10.4. Small Molecules
11. Solid Tumors Target Proteins Market, by Mechanism Of Action
11.1. Allosteric Inhibitors
11.2. Dna Damage Agents
11.3. Hormone Receptor Antagonists
11.4. Immune Checkpoint Blockers
11.5. Receptor Tyrosine Kinase Inhibitors
12. Solid Tumors Target Proteins Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Solid Tumors Target Proteins Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Solid Tumors Target Proteins Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Solid Tumors Target Proteins Market
16. China Solid Tumors Target Proteins Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. AstraZeneca PLC
17.8. Bayer AG
17.9. Boehringer Ingelheim International GmbH
17.10. Bristol-Myers Squibb Company
17.11. Celgene Corporation
17.12. Daiichi Sankyo Company, Limited
17.13. Eli Lilly and Company
17.14. Genentech, Inc.
17.15. GlaxoSmithKline plc
17.16. Janssen Pharmaceuticals, Inc.
17.17. Johnson & Johnson
17.18. Merck & Co., Inc.
17.19. Novartis AG
17.20. Pfizer Inc.
17.21. Regeneron Pharmaceuticals, Inc.
17.22. Roche Holding AG
17.23. Sanofi
17.24. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 162. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 165. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 166. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 167. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 169. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 170. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 171. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 172. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 184. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 187. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 188. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 189. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 190. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 191. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 192. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 193. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 194. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 209. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 210. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 211. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 213. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 214. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 216. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 217. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 218. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 220. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 221. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 222. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 223. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 224. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 225. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 226. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 227. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 228. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 240. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 242. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 243. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 244. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 245. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 246. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 247. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 248. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 249. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 250. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 251. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 252. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 253. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 254. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 255. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 256. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 258. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 259. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 260. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 261. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 262. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 263. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 264. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 265. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 266. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 267. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 268. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 269. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 271. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 272. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 273. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 278. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 279. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 285. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 286. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 287. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 288. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 289. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
TABLE 290. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 291. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
TABLE 292. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 293. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 294. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 295. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Solid Tumors Target Proteins market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.18 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Reports

Recombinant Humanized Bisspecific Antibody Market - Global Forecast 2025-2030 - Product Image

Recombinant Humanized Bisspecific Antibody Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
CD40 Ligand Market - Global Forecast 2026-2032 - Product Image

CD40 Ligand Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025 - Product Image

Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • 180 Pages
  • Global
From
VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025 - Product Image

VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025

  • Report
  • 75 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.